Rhumbline Advisers Evelo Biosciences, Inc. Transaction History

Rhumbline Advisers

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.46 - $3.55 $42,084 - $102,328	-28,825 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.66 - $6.63 $12,980 - $32,354	4,880 Added 20.38%	28,825 $98,000
Q4 2021 Feb 10, 2022	BUY	$6.07 - $12.0 $1,899 - $3,756	313 Added 1.32%	23,945 $145,000
Q3 2021 Nov 12, 2021	BUY	$6.79 - $13.9 $6,885 - $14,094	1,014 Added 4.48%	23,632 $166,000
Q2 2021 Aug 05, 2021	BUY	$9.43 - $16.6 $28,431 - $50,049	3,015 Added 15.38%	22,618 $311,000
Q1 2021 May 06, 2021	BUY	$9.71 - $18.6 $2,126 - $4,073	219 Added 1.13%	19,603 $210,000
Q4 2020 Feb 10, 2021	BUY	$3.91 - $12.28 $8,562 - $26,893	2,190 Added 12.74%	19,384 $234,000
Q3 2020 Nov 12, 2020	SELL	$3.81 - $5.73 $2,247 - $3,380	-590 Reduced 3.32%	17,194 $91,000
Q2 2020 Aug 13, 2020	SELL	$3.53 - $6.12 $8,980 - $15,569	-2,544 Reduced 12.51%	17,784 $87,000
Q4 2019 Feb 05, 2020	BUY	$3.81 - $7.45 $1,066 - $2,086	280 Added 1.4%	20,328 $83,000
Q3 2019 Oct 23, 2019	BUY	$5.45 - $8.8 $7,788 - $12,575	1,429 Added 7.67%	20,048 $122,000
Q2 2019 Aug 14, 2019	BUY	$6.52 - $9.42 $22,304 - $32,225	3,421 Added 22.51%	18,619 $167,000
Q1 2019 May 01, 2019	BUY	$7.5 - $15.31 $113,985 - $232,681	15,198 New	15,198 $122,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.